<p>Abbreviations: AE = adverse event; CI = confidence interval; CR = complete response; HFSR = hand foot skin reaction; NE = estimable; NR = not reported; OS = overall survival; PFS = progression-free survival; PR = partial response; SD = stable disease.</p><p><sup>a</sup> NR for 3 patients.</p><p><sup>b</sup> Tumor assessment was not possible in five patients and they were excluded from the efficacy analysis.</p><p><sup>c</sup> Treatment emergent AEs were reported for the total 202 patients, which included both patients randomized to the sorafenib and to the placebo arm after a 12 week run-in period of sorafenib treatment.</p><p><sup>d</sup> Interim analysis.</p><p><sup>e</sup> Median overall survival was not reached.</p><p><sup>f</sup> Unconfirmed.</p><p><sup>g</sup> All reported AEs were considered treatment related.</p><p><sup>h</sup> Grade ≥3.</p><p><sup>i</sup> Including 2 grade 5.</p><p>Phase 2 trials of sorafenib in RCC published following the TARGET trial.</p
